NASDAQ:NVET NEXVET BIOPHARMA PUB LTD CO
Even after a poor earnings report NVET shows a nice spike starting in May 2016. The cause for positive growth over a poor earnings can be attributed to positive analyst review valuing the company @ $12 in the next year. Additionally, positive statistical results have been reported by NVET hastening their growth. The question is can we expect continued growth in the company. I have laid out predictive to estimate the risk-reward and the possible points for rallys.